New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Check below for free stories on GOOG;EMC;VMW;INTC;GILD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 15, 2014
15:03 EDTGILDGilead treatment of chronic lymphocytic leukemia granted orphan status
The FDA granted the orphan designation on April 14, according to a post to the regulator's website. Reference Link
14:25 EDTINTCIntel April option elevated into Q1 and outlook
Intel April call option implied volatility is at 41, May is at 21, June and October is at 19; compared to its 26-week average of 21 according to Track Data, suggesting large near term price movement into the release of Q1 results today after the market close.
13:49 EDTINTCEarnings Preview: Analysts optimistic on Intel ahead of Q1 report
Subscribe for More Information
13:18 EDTGOOGDaniel Graf to join Twitter's product team
Daniel Graf, who led efforts on Google Maps (GOOG), is joining Twitter's (TWTR) product team, Graf announced in a tweet. Reference Link
12:45 EDTGOOGEarnings Preview: Google shares down 8% since last earnings report
Google (GOOG, GOOGL) is expected to report first quarter earnings after the market close on Wednesday, April 16 with a conference call scheduled for 4:30 pm ET. Google is a global technology company that focuses on Internet search, cloud computing, and advertising technologies. EXPECTATIONS: Analysts are looking for earnings per share of $6.39 on revenue of $15.52B. The consensus range is $5.83-$6.96 for EPS, and $14.94B-$16.12B for revenue, according to First Call. LAST QUARTER: Google reported Q4 EPS $12.01 against estimates of $12.26 on revenue of $16.86B against estimates of $16.75B. Google reported Q4 paid clicks up 31% and average cost-per-click decreased approximately 11%. The company also reported Q4 Sites revenue $10.55B and Q4 Network revenue $3.52B. NEWS: Google effectively split its stock with a dividend distribution of Class C shares, which began trading in early April. In the past quarter, the company reached a deal with a European Union after sending an improved commitments proposal in context of the ongoing antitrust investigation on online search and search advertising. Google also announced that it resolved the copyright litigation with Viacom (VIA, VIAB). The company announced partnerships and agreements with VMware (VMW), Cisco (CSCO), and OmniVision (OVTI) as well as acquisitions of SlickLogin, Titan Aerospace and parts of Green Throttle Games. STREET RESEARCH: Cantor said Google is being boosted by product listing ads, which are expected to increase the company's 2014 ad revenue by $1B. Atlantic Equities and Bernstein said Google's weakness provides a buying opportunity, citing strong year-over-year revenue growth at "core Google." Bernstein added predictions that Google Play, Computer and App Engine, and Apps for Enterprise and government will become multi-billion dollar businesses. Ahead of the Q1 earnings, Susquehanna said the results should beat expectations due to continued website growth, PLAs, and early benefits from Enhanced Campaigns and YouTube. PRICE ACTION: Google shares have dropped over 8% since the first day of trading following the company's Q4 report. In Tuesday midday trading ahead of Q1 report, Google shares are down a little over 2%.
08:39 EDTGOOGNetlist patent with LRDIMM claims confirmed in reexamination
Subscribe for More Information
08:20 EDTGOOGAeroVironment has limited comparability to Google acquisition, says CRT Capital
Subscribe for More Information
07:11 EDTGOOGLattice FPGAs selected by Google ATAP Group for Project Ara smartphone prototype
Subscribe for More Information
06:46 EDTGOOGGoogle price target raised to $700 from $650 at Jefferies
Jefferies raised its price target for Google shares to $700 ahead of the company's Q1 results on Wednesday and it keeps a Buy rating on the stock. The new price target reflects the sale of Motorola. Jefferies notes its survey indicates Google's traffic trends were solid in Q1.
06:38 EDTGOOGGoogle to use satellites to take photos, expand use of Internet, NY Times says
Google said that it would use Titan Aerospace's drone satellites to take photos of the Earth and connect people to the Internet, according to The New York Times. Google announced yesterday that it would buy Titan. Reference Link
06:02 EDTGOOGGoogle Glass goes on sale to U.S. residents today, USA Today reports
Beginning at 9 am ET, Google Glass will be available for U.S. residents for $1,500 plus tax, USA Today reports. This one-day sale is an expansion of the company's 2012 Glass Explorer program. Reference Link
April 14, 2014
16:00 EDTGILDOptions Update; April 14, 2014
iPath S&P 500 VIX Short-Term Futures down 32c to 44.41. Option volume leaders: AAPL C GILD TSLA LNG NQ BAC ZNGA according to Track Data.
14:06 EDTGOOGGoogle to acquire Titan Aerospace, WSJ says
Subscribe for More Information
13:32 EDTGOOGGoogle April volatility elevated at 68 into Q1 and revenue outlook
Subscribe for More Information
10:02 EDTVMWOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:09 EDTGILDGilead poised to be leader in all-oral HCV treatment, says Wells Fargo
After attending the EASL conference, Wells Fargo believes that Gilead's HCV treatment has multiple advantages over the competition. The firm keeps an Outperform rating on the stock.
09:01 EDTVMW, VMWVMware upgraded to Outperform from Underperform at CLSA
Subscribe for More Information
08:15 EDTGILDBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
07:59 EDTGILDGilead Sovaldi should take majority share of HCV market, says Stifel
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use